ArticleHaematologica2024

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.

Hamza Hashmi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.